What is the ticker symbol for Inhibrx Biosciences?

Inhibrx Biosciences trades under the ticker INXB on NASDAQ.

What sector does Inhibrx Biosciences operate in?

Inhibrx Biosciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze INXB in a portfolio?

PortView shows INXB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Inhibrx Biosciences (INXB) Stock Analysis

NASDAQHealthcareBiotechnology

$15.86+13.94%

1-year price historyRange $13.92 – $18.02

52-week range$15.86

$12.95$18.95

What Inhibrx Biosciences does

Inhibrx Biosciences, Inc. operates as a clinical-stage biopharmaceutical entity, primarily focused on developing advanced biologic treatments for critical, life-threatening medical conditions. Key assets within its development pipeline include: INBRX-109, a tetravalent investigational therapy, is progressing through Phase 2 clinical trials. It is specifically engineered to target death-receptor 5 for the management of advanced, unresectable, or metastatic conventional chondrosarcoma. INBRX-106, a hexavalent sdAb-based investigational treatment targeting OX4, is also in Phase 2 clinical development. This candidate is being evaluated for its potential to treat a diverse array of metastatic solid tumors, encompassing non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancers, renal cell carcinoma, and urothelial (transitional) cell carcinoma. Established in 2024, Inhibrx Biosciences maintains its headquarters in La Jolla, California.

Key metrics

Market cap

$225.87M

P/E (TTM)

0.00

Beta

2.88

Dividend yield

0.00%

Revenue / share

$0.00

50-day avg

$16.45

200-day avg

$16.45

52-week high

$18.95

52-week low

$12.95

CEO

Mark Paul Lappe

ETFs linked to INXB

Broad-market and Healthcare sector ETFs an investor holding Inhibrx Biosciences is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how INXB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze INXB in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Inhibrx Biosciences?: Inhibrx Biosciences trades under the ticker INXB on NASDAQ.
Which exchange is INXB listed on?: INXB is listed on NASDAQ.
What sector does Inhibrx Biosciences operate in?: Inhibrx Biosciences is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze INXB in a portfolio?: PortView shows INXB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.